Bicyclic Spiro Compounds Selective M1 Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic strategies for Alzheimer's disease, insulin resistance syndrome, and type 2 diabetes that target protein kinase C (PKC) activators and Glycogen synthase kinase-3β (GSK-3β) face challenges due to non-selective modulation of kinases, leading to off-target side effects, and there is a need for more potent and selective ligands that can modulate specific pathways involved in these diseases without desensitizing GPCR-mediated signaling.
Innovation Solution
Development of bicyclic spiro compounds that act as selective M1 muscarinic receptor modulators, which can activate PKC and inhibit GSK-3β, thereby reducing neurotoxic amyloid formation and tau hyperphosphorylation, and are designed to prevent desensitization of GPCR signaling, thereby minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If direct modulators of PKC or GSK-3β are used, then therapeutic effect on Alzheimer's disease and metabolic diseases is improved, but off-target side effects increase due to non-selective modulation
Solution Approach 1:
The patent employs GPCRs as intermediary proteins to indirectly modulate PKC and GSK-3β. Instead of directly targeting the kinases (which causes off-target effects), the compounds first bind to GPCRs, which then activate PKC and inhibit GSK-3β through downstream signaling pathways. This intermediary approach provides selectivity and reduces harmful side effects while maintaining therapeutic efficacy.
Solution Approach 2:
The patent modifies the molecular structure of GPCR ligands by introducing specific bicyclic spiro heterocyclic moieties with particular stereochemistry and substituent patterns. These structural parameter changes enable selective binding to specific GPCR subtypes (such as M1 muscarinic receptor), thereby achieving pathway-specific modulation of PKC and GSK-3β without affecting other targets.
2Object-affected harmful factors
If potent GSK-3β inhibitors are used, then neurotoxicity and amyloid formation are reduced, but desensitization of GPCR signaling occurs
Solution Approach 1:
The patent employs partial agonists at GPCR receptors rather than full agonists. These partial agonists provide sufficient activation to trigger downstream PKC and GSK-3β modulation, achieving neuroprotective effects, while avoiding the excessive signaling that leads to receptor desensitization and internalization. The partial activation is sufficient for therapeutic benefit without causing harmful adaptive responses.
3Adaptability or versatility
If non-selective kinase modulators are used, then broad therapeutic coverage is achieved, but specificity and safety are reduced
Solution Approach 1:
The patent achieves tissue-specific and receptor-subtype-specific modulation through compounds that selectively bind to particular GPCR subtypes expressed in specific tissues. The bicyclic spiro heterocyclic structures provide steric and electronic properties that confer high affinity and selectivity for specific GPCRs (e.g., M1 muscarinic receptor in the brain), thereby achieving localized therapeutic effect without system-wide side effects.
Data Source
AI summary
There are provided certain bicyclic heterocyclic compounds that act as M1 muscarinic receptor modulators. Compositions containing these compounds and their use are also disclosed.